Related ArticlesAdalimumab in psoriatic arthritis : a viewpoint by eric ruderman.
Drugs. 2006;66(11):1497-9
Authors: Ruderman E
PMID: 16906785 [PubMed - in process]
]]>
Adalimumab in psoriatic arthritis: a viewpoint by andrea doria and paolo sfriso.
Drugs. 2006;66(11):1497-9
Authors: Doria A, Sfriso P
PMID: 16906784 [PubMed - in process]
]]>
Adalimumab in psoriatic arthritis : a viewpoint by philip mease.
Drugs. 2006;66(11):1497-9
Authors: Mease P
PMID: 16906783 [PubMed - in process]
]]>
Adalimumab : in psoriatic arthritis.
Drugs. 2006;66(11):1487-96
Authors: Simpson D, Scott LJ
black triangle Adalimumab, a fully human monoclonal antibody, is a tumour necrosis factor antagonist that has been investigated for efficacy in psoriatic arthritis, based on well-established use of the drug in rheumatoid arthritis.black triangle In well-controlled Phase III trials, adalimumab (40 mg administered subcutaneously every other week) has shown efficacy in adult patients with psoriatic arthritis who had an inadequate response to previous treatment with NSAIDs (24-week ADEPT trial; n = 313) or disease-modifying antirheumatic drugs (12-week study; n = 100).black triangle In these trials, adalimumab recipients experienced a significantly greater improvement in arthritis response (p /=10% )Most frequently reportedInjection-site reactions, upper respiratory tract infection, headache, rash and sinusitis.
PMID: 16906782 [PubMed - in process]
]]>